Publication number: 20220235376
Abstract: The invention relates to preparing and using recombinant expression vectors for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2. One expression vector contains the recombinant human adenovirus serotype26 genome, wherein the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an integrated expression cassette of SEQ ID NO:1, 2, or 3 (variant 1). Therein, SEQ ID NO:5 was a parental sequence of human adenovirus serotype 26. Another expression vector contains the recombinant simian adenovirus serotype25 genome, wherein the E1 and E3 regions are deleted, with an integrated expression cassette of SEQ ID NO:4, 2, or 3 (variant 2). Therein, SEQ ID NO:6 was a parental sequence of simian adenovirus serotype 25. Further, the recombinant human adenovirus serotype5 genome is disclosed, wherein the E1 and E3 regions are deleted, with an integrated expression cassette of SEQ ID NO:1, 2, or 3 (variant 3).
Type:
Application
Filed:
March 31, 2022
Publication date:
July 28, 2022
Inventors:
Olga Vadimovna ZUBKOVA, Tatiana Andreevna Ozharovskaia, Inna Vadimovna Dolzhikova, Olga Popova, Dmitrii Viktorovich Shchebliakov, Daria Mikhailovna Grousova, Alina Shahmirovna Dzharullaeva, Amir IIdarovich Tukhvatulin, Natalia Mikhailovna Tukhvatulina, Dmitrii Nikolaevich Shcherbinin, IIias Bulatovich Esmagambetov, Elizaveta Alexsandrovna Tokarskaya, Andrei Gennadevich Botikov, Alina Sergeevna Eroxova, Natalya Anatolevna Nikitenko, Aleksandr Sergeevich Semikhin, Sergey Vladimirovich Borisevich, Boris Savelievich Naroditsky, Denis Yuryevich Logunov, Aleksandr Leonidovich Gintsburg
